Octreoscan (Indium In-111 Pentetreotide)

Octreoscan is a radiolabeled somatostatin analogue that targets somatostatin receptor‑positive neuroendocrine tumors.

• Gastroenteropancreatic neuroendocrine tumors: helps detect the presence and anatomical distribution of disease.
• Carcinoid syndrome tumors: assists in staging and therapeutic planning by visualising receptor‑positive lesions.
• Medullary thyroid carcinoma: aids in identifying metastatic sites for surgical or systemic treatment decisions.
• Small‑cell lung cancer (rare indication for imaging research).

• Indium In-111 pentetreotide binds selectively to somatostatin receptor subtype 2 (SSTR2) on the surface of neuroendocrine tumor cells. After intravenous injection, the radiolabelled peptide circulates, attaches to SSTR2‑expressing cells, and emits gamma photons that are captured by a gamma camera, producing high‑resolution images of tumor location and burden.

Adverse reactions are generally related to the radiopharmaceutical and the injection process.

Common Side Effects

• Nausea: mild to moderate, often transient.
• Flushing: brief erythema and warmth, usually self‑limiting.
• Headache: mild discomfort occurring shortly after administration.
• Injection site pain: localized tenderness at the venous access point.
• Transient hypotension: brief drop in blood pressure during or after injection.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rapid onset of airway swelling, hives, or circulatory collapse.
• Significant radiation‑induced organ toxicity: especially to kidneys or bone marrow with high cumulative exposure.
• Persistent hypotension requiring medical intervention.
• Acute hemolysis or hematuria.
• Development of secondary malignancies (theoretical risk with high cumulative doses).

Octreoscan should be used only under the supervision of physicians experienced in nuclear medicine imaging.

• Pregnancy testing: perform before administration because radiation may affect fetal development.
• Breastfeeding: discontinue nursing for an appropriate period after dosing due to possible radiotracer excretion.
• Renal function: assess baseline kidney function; adjust or avoid in severe impairment.
• Concomitant radiopharmaceuticals: avoid simultaneous use to prevent overlapping radiation exposure.
• Allergic history: verify no prior severe reaction to somatostatin analogues or indium‑based agents.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreoscan may interact with other agents that influence radiation exposure or somatostatin receptor activity.

Major Interactions (Avoid)

• Concurrent radiopharmaceuticals: may lead to additive radiation dose and increased toxicity.
• High‑dose somatostatin analog therapy (e.g., octreotide infusion): can compete for receptor binding and reduce imaging quality.

Moderate Interactions (Monitor Closely)

• Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs): may exacerbate renal radiation exposure.
• Diuretics: can alter renal clearance of the tracer, affecting dosimetry.
• Antihistamines or steroids: may mask mild allergic reactions, delaying recognition.
• Chemotherapy agents: consider timing to avoid overlapping toxicity.
• Contrast agents used in CT: schedule appropriately to prevent image artefacts.